May 18, 2020 / 03:40PM GMT
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello. Welcome to the UBS Global Healthcare Conference. This is day 1. Our next presentation or fireside chat is with Merck & Co. I'm very happy to have with me today, EVP and Chief Marketing Officer, Mike Nally; as well as Head of Investor Relations, Peter Dannenbaum. Mike, Peter, thank you so much for joining us today.
Michael T. Nally - Merck & Co., Inc. - CMO & Executive VP
Thanks, Navin. We appreciate the opportunity.
Peter Dannenbaum - Merck & Co., Inc. - VP of IR
Thanks, Navin.
Questions and Answers:
Navin Cyriac Jacob - UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap PharmaceuticGreat. So we -- we're just going to jump into questions here. We can't escape COVID, obviously, and so maybe I'll just start off with a couple of high-level questions